Tempest Therapeutics Files 8-K with Financial Updates
Ticker: TPST · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001544227
| Field | Detail |
|---|---|
| Company | Tempest Therapeutics, Inc. (TPST) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, sec-filing, operations
TL;DR
Tempest Therapeutics dropped its 8-K on 3/30/26 - check financials!
AI Summary
On March 30, 2026, Tempest Therapeutics, Inc. filed an 8-K report detailing its financial results and condition. The filing includes information related to its operations and financial statements, with exhibits such as an iXBRL 8-K and other financial documents.
Why It Matters
This filing provides investors with crucial, up-to-date information on Tempest Therapeutics' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings are routine, but the specific financial details within can reveal significant positive or negative developments for the company.
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Filer of the 8-K report
- 0001544227 (company) — CIK number for Tempest Therapeutics, Inc.
- 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 (location) — Mailing and Business Address for Tempest Therapeutics, Inc.
- 415-798-8589 (phone_number) — Business phone number for Tempest Therapeutics, Inc.
- 2026-03-30 (date) — Filing date and period of report for the 8-K
FAQ
What specific financial results are detailed in the 8-K filing?
The 8-K filing, specifically Item 2.02, covers Results of Operations and Financial Condition, but the exact figures are not provided in the filing header.
When was this 8-K filing accepted by the SEC?
The filing was accepted on March 30, 2026, at 08:28:11.
What are the main documents included in this filing?
The filing includes an iXBRL 8-K, an exhibit EX-99.1, and other graphic and text files.
What is Tempest Therapeutics, Inc.'s business address?
The business address is 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005.
What is the CIK number for Tempest Therapeutics, Inc.?
The CIK number for Tempest Therapeutics, Inc. is 0001544227.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2026-03-30 08:28:11
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value TPST The Nasdaq Stock Mar
Filing Documents
- tpst-20260330.htm (8-K) — 50KB
- tpst-ex99_1.htm (EX-99.1) — 187KB
- img73128808_0.jpg (GRAPHIC) — 24KB
- 0001193125-26-130480.txt ( ) — 416KB
- tpst-20260330.xsd (EX-101.SCH) — 44KB
- tpst-20260330_htm.xml (XML) — 6KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 30, 2026, Tempest Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the year ended December 31, 2025 and other business highlights. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including Exhibit 99.1 hereto) is being furnished under "Item 2.02 Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated March 30, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEMPEST THERAPEUTICS, INC. Date: March 30, 2026 By: /s/ Matthew Angel Name: Matthew Angel Title: Chief Executive Officer